Renal cell carcinoma
Bevacizumab, Sorafenib, Sunitinib and Temsirolimus.
TA178 Bevacizumab, sorafenib, sunitinib and temsirolimus for advanced and/or metastatic renal cell carcinoma
Response from the DSU to comments on the extra work consultation (PDF, 16KB) (February 2009)
Extra work done by the DSU on the revised analyses submitted by Bayer (PDF, 54KB) (January 2009)
DSU addendum to the review of Roche’s request for parameter changes (PDF, 17KB) (January 2009)
Bevacizumab, sorafenib, sunitinib and temsirolimus for renal cell carcinoma (PDF, 133KB) (September 2008)
Additional analysis by assessment group and DSU (PDF, 711KB) (September 2008)
A world top-100 university
We're a world top-100 university renowned for the excellence, impact and distinctiveness of our research-led learning and teaching.